Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$12.97 +3.7%	$15.58	$10.96 ▼ $32.97	$690.35M	2.22	1.34 million shs	1.27 million shs
CORBF Global Cord Blood	$1.55 -0.6%	$1.01	$0.25 ▼ $1.75	$188.40M	-0.6	95,119 shs	606 shs
CSTL Castle Biosciences	$20.84 +4.4%	$18.74	$14.59 ▼ $35.84	$604.53M	1.09	702,169 shs	354,984 shs
FLGT Fulgent Genetics	$21.77 +1.7%	$19.66	$14.57 ▼ $23.99	$666.36M	0.83	337,827 shs	190,521 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	0.00%	+9.54%	+1.01%	-23.48%	-61.12%
CORBF Global Cord Blood	0.00%	+181.82%	+181.82%	+55.00%	-11.43%
CSTL Castle Biosciences	0.00%	+3.73%	+26.84%	+29.44%	-25.17%
FLGT Fulgent Genetics	0.00%	+2.40%	+18.25%	+7.19%	-7.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDNA CareDx	4.305 of 5 stars	3.3	2.0	0.0	4.2	2.7	0.8	1.9
CORBF Global Cord Blood	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CSTL Castle Biosciences	2.5422 of 5 stars	3.5	3.0	0.0	0.0	2.9	1.7	0.0
FLGT Fulgent Genetics	3.6765 of 5 stars	2.3	1.0	0.0	4.1	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.67	Moderate Buy	$27.67	113.31% Upside
CORBF Global Cord Blood	0.00	N/A	N/A	N/A
CSTL Castle Biosciences	3.00	Buy	$37.00	77.54% Upside
FLGT Fulgent Genetics	2.67	Moderate Buy	$25.33	16.37% Upside

Current Analyst Ratings Breakdown

Latest CORBF, FLGT, CDNA, and CSTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CDNA CareDx	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$19.00 ➝ $14.00
8/5/2025	FLGT Fulgent Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$20.00 ➝ $30.00
8/4/2025	FLGT Fulgent Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$23.00 ➝ $21.00
7/18/2025	CDNA CareDx	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $26.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$333.79M	2.07	$1.36 per share	9.54	$7.06 per share	1.84
CORBF Global Cord Blood	$196.12M	0.96	$1.11 per share	1.40	N/A	∞
CSTL Castle Biosciences	$332.07M	1.82	$0.98 per share	21.18	$16.28 per share	1.28
FLGT Fulgent Genetics	$283.47M	2.35	N/A	N/A	$36.92 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	$52.55M	$1.02	12.72	N/A	N/A	17.97%	18.03%	12.88%	11/3/2025 (Estimated)
CORBF Global Cord Blood	$79.04M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CSTL Castle Biosciences	$18.25M	-$0.35	59.54	N/A	N/A	-2.73%	2.37%	2.03%	11/3/2025 (Estimated)
FLGT Fulgent Genetics	-$42.71M	-$1.66	0.00	N/A	N/A	-16.83%	-2.26%	-2.10%	N/A

Latest CORBF, FLGT, CDNA, and CSTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	CDNA CareDx	$0.12	-$0.16	-$0.28	-$0.16	$90.72 million	$90.51 million
8/4/2025	Q2 2025	CSTL Castle Biosciences	-$0.51	$0.15	+$0.66	$0.15	$71.53 million	$86.18 million
8/1/2025	Q2 2025	FLGT Fulgent Genetics	-$0.23	$0.07	+$0.30	-$0.62	$76.21 million	$81.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
CORBF Global Cord Blood	N/A	N/A	N/A	N/A	N/A
CSTL Castle Biosciences	N/A	N/A	N/A	N/A	N/A
FLGT Fulgent Genetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	3.30	3.00
CORBF Global Cord Blood	N/A	N/A	N/A
CSTL Castle Biosciences	0.02	6.85	6.69
FLGT Fulgent Genetics	N/A	6.01	6.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
CORBF Global Cord Blood	N/A
CSTL Castle Biosciences	92.60%
FLGT Fulgent Genetics	48.06%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	4.40%
CORBF Global Cord Blood	0.50%
CSTL Castle Biosciences	7.20%
FLGT Fulgent Genetics	33.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	53.23 million	50.89 million	Optionable
CORBF Global Cord Blood	1,200	121.55 million	N/A	Not Optionable
CSTL Castle Biosciences	540	29.01 million	26.92 million	Optionable
FLGT Fulgent Genetics	1,313	30.61 million	20.47 million	Optionable

CORBF, FLGT, CDNA, and CSTL Headlines

Recent News About These Companies

Fulgent Genetics, Inc. $FLGT Shares Bought by Deutsche Bank AG

August 19, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Increases Stock Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

August 15, 2025 | marketbeat.com

XTX Topco Ltd Takes $324,000 Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

August 11, 2025 | marketbeat.com

Fulgent Genetics (FLGT) Receives a Hold from Piper Sandler

August 9, 2025 | theglobeandmail.com

Fulgent Genetics (NASDAQ:FLGT) Shares Up 9.3% - Here's Why

August 6, 2025 | marketbeat.com

Fulgent Genetics (NASDAQ:FLGT) Raised to "Buy" at UBS Group

August 6, 2025 | marketbeat.com

UBS Upgrades Fulgent Genetics (FLGT)

August 6, 2025 | msn.com

Fulgent Genetics (NASDAQ:FLGT) Shares Down 3.4% Following Analyst Downgrade

August 5, 2025 | marketbeat.com

Fulgent Genetics (NASDAQ:FLGT) Price Target Lowered to $21.00 at Piper Sandler

August 5, 2025 | marketbeat.com

Fulgent Genetics’ Earnings Call Highlights Growth and Optimism

August 4, 2025 | theglobeandmail.com

Fulgent Genetics (NASDAQ:FLGT) Announces Quarterly Earnings Results

August 3, 2025 | marketbeat.com

Fulgent Genetics (NASDAQ:FLGT) Shares Gap Up After Earnings Beat

August 2, 2025 | marketbeat.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2025 Earnings Call Transcript

August 2, 2025 | insidermonkey.com

Fulgent Genetics (NASDAQ:FLGT) Updates FY 2025 Earnings Guidance

August 2, 2025 | marketbeat.com

Fulgent (FLGT) Q2 Revenue Jumps 16%

August 2, 2025 | fool.com

Why Fulgent Genetics Stock Was Crushing It on Friday

August 1, 2025 | fool.com

Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

Fulgent Genetics, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 1, 2025 | seekingalpha.com

Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates

August 1, 2025 | zacks.com

1FLGT : Fulgent Genetics Earnings Preview

July 31, 2025 | benzinga.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Sold by Bank of New York Mellon Corp

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORBF, FLGT, CDNA, and CSTL Company Descriptions

CareDx NASDAQ:CDNA

$12.97 +0.46 (+3.68%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.82 -0.15 (-1.12%)

As of 08/22/2025 07:45 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Global Cord Blood NYSE:CORBF

$1.55 -0.01 (-0.64%)

As of 08/22/2025 09:40 AM Eastern

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Castle Biosciences NASDAQ:CSTL

$20.84 +0.87 (+4.36%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$20.60 -0.24 (-1.15%)

As of 08/22/2025 05:10 PM Eastern

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Fulgent Genetics NASDAQ:FLGT

$21.77 +0.37 (+1.73%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$21.81 +0.04 (+0.18%)

As of 08/22/2025 05:50 PM Eastern

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time